Archive for the 'Lupus' Category
Continued Treatment For Lupus May Boost Survival Of Those Patients With End-Stage Kidney Disease
Researchers at Albert Einstein College of Medicine of Yeshiva University have shown that close supervision by rheumatologists and the use of immunosuppressant drugs improve the survival of lupus patients with end-stage kidney disease a finding that could reverse long-standing clinical practice. Their study appeared in the September 1 online edition of the Journal of Rheumatology. At least 1…
Original post by Wife of a Diabetic
No commentsNew Genetic Clue In The Development Of Rheumatoid Arthritis
Scientists at Mount Sinai Hospital, in collaboration with researchers at the University of Toronto, University Health Network and McGill University have obtained significant new insights into the causes of rheumatoid arthritis (RA) and other autoimmune disorders including type 1 diabetes, lupus and Graves disease…
Original post by Six Until Me.
No commentsVitamin D Deficiency Among Systemic Lupus Erythematosis Patients
Researchers have just found that vitamin D levels among systemic lupus erythematosis (SLE) patients directly relates to the severity of the disease and the development of the infection. The study found that people with low levels of vitamin D are more prone to develop SLE than those with higher levels…
Original post by Six Until Me.
No commentsGlaxo’s Revolutionary Lupus Treatment Benlysta Now EU Approved
The first treatment developed for lupus in over 50 years has finally been approved by the European Union this week. The watchdog, European Medicines Agency, has backed the injectable drug that will cost Europeans $23,000 USD a year. Already approved in the United States in March 2011, the drug costs Americans $35,000 USD annually. Benlysta’s annual global sales are expected to reach $3…
Original post by Six Until Me.
No commentsStudy Of African-American Women Reveals New Genetic Risk Factors Of Lupus
Researchers from Boston University’s Slone Epidemiology Center have found four new genetic variants in the major histocompatibility complex (MHC) that confer a higher risk of systemic lupus erythemathosus (“lupus”) in African American women…
Original post by Six Until Me.
No commentsSurvey Reveals Lupus’ Ability To Wreck Careers
Lupus has a profoundly negative effect on the working lives of sufferers’, found a survey of over 2,000 lupus patients presented at the Annual Meeting of the European League Against Rheumatism (EULAR) in London, May 25-28. “We’ve shown just how debilitating lupus can be in terms of the number of patients having to stop work, change their jobs or apply for sick leave…
Original post by Lemonade Life
No commentsResults Showed 7 Out Of 10 Patients Reported That Lupus Affected Their Careers
LUPUS EUROPE (LE) and UCB today announced results from the pan-European Lupus European Online (LEO) survey, believed to be the first online survey of its kind completed by lupus patients using validated measures assessing the impact of lupus. These patient-reported outcome (PRO) measures included assessments of fatigue, work impairment and health-related quality of life…
Original post by Pharmalot
No commentsDisease Activity In Systemic Lupus Erythematosus Patients Not Increased By The HPV Vaccine Gardasil
Results of a Chinese study showed that the HPV vaccine did not have significant effects on the number of disease flares or antibody measures in patients with inactive SLE receiving stable doses of medications after administration, and therefore was determined safe to use to prevent HPV in this group of patients…
Original post by Pharmalot
No commentsGlaxoSmithKline And Human Genome Sciences Receive Positive Opinion In Europe From The CHMP For Benlysta® (belimumab)
GlaxoSmithKline (GSK) and Human Genome Sciences, Inc…
Original post by Genetics and Health
No commentsGSK Lupus Treatment Benlysta Reaches Europe After US Approval
The first treatment developed for lupus in over 50 years has been reocommended for approval by the European Union this week. The watchdog, European Medicines Agency has backed the injectable drug that will cost Europeans $23,000 USD a year. Already approved in the United States in March 2011, the drug costs Americans $35,000 USD annually…
Original post by Genetics and Health
No comments